Friday, 17 January 2025 11:30 AM
Class Action
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) concerning possible violations of federal securities laws.
IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases." The press release quoted Mary Beth Harler, M.D., the Company's Chief Executive Officer, as stating that "[i]nterim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success[.]"
Following this news, IGM's stock price fell over 66% on January 10, 2025. To obtain additional information, go to:
https://zlk.com/pslra-1/igm-biosciences-inc-lawsuit-submission-form?prid=123451&wire=1
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP